Literature DB >> 11193887

The cascade radical annulation approach to new analogues of camptothecins. Combinatorial synthesis of silatecans and homosilatecans.

D P Curran1, H Josien, D Bom, A E Gabarda, W Du.   

Abstract

An overview of the cascade radical annulation approach to the camptothecin family of antitumor drugs is presented. This combinatorial synthetic approach involves two key steps: (1) N-propargylation of a lactone/pyridone D/E ring fragment and (2) cascade radical annulation of an A-ring isonitrile to form rings B and C. The synthesis is probably the most flexible and general route to the camptothecin class of molecules. The parallel synthesis of several libraries of silatecan and homosilatecan libraries is summarized. One of the first-generation silatecans, DB-67, is emerging as a serious candidate for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193887     DOI: 10.1111/j.1749-6632.2000.tb07030.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.

Authors:  Eleftheria Tsakalozou; Eyob D Adane; Kuei-Ling Kuo; Abigail Daily; Jeffrey A Moscow; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

2.  Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.

Authors:  Fei Tang; Eleftheria Tsakalozou; Susanne M Arnold; Chee M Ng; Markos Leggas
Journal:  Invest New Drugs       Date:  2019-02-28       Impact factor: 3.850

Review 3.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.

Authors:  Susanne M Arnold; John J Rinehart; Eleftheria Tsakalozou; John R Eckardt; Scott Z Fields; Brent J Shelton; Philip A DeSimone; Bryan K Kee; Jeffrey A Moscow; Markos Leggas
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.